has also recently been suggested as a potential biomarker of mitochondrial disease; however, in view of the number of variables that may influence the circulatory level of this compound, its diagnostic value requires careful consideration [9] .
The determination of coenzyme Q 10 (CoQ 10 ) in plasma or blood mononuclear cells (BMNCs) appears to be of diagnostic utility in identifying patients with a deficit in the level of thisisoprenoid [10] . However, although this determination can't distinguish between primary or secondary CoQ 10 deficiencies, it identifies an important subset of mitochondrial patients that may respond to CoQ 10 supplementation [11] . The use of BMNC's also offers a means to directly assess MRC enzyme activities in patients with suspected mitochondrial disease, although a 'normal' result does not exclude the possibility that a defect may be expressed in other tissues [12] .
The assessment of oxidative stress is also an important consideration in the context of mitochondria disease; although not a diagnostic parameter, it can provide important information about disease pathophysiology as well as the therapeutic efficacy of antioxidant strategies. The intracellular redox status of the antioxidant, reduced glutathione (GSH), as indicated by the ratio of GSH to its fully oxidised form, GSSG in white blood cells or BMNCs, may offer an appropriate surrogate for this evaluation [13] .
Overall, at present, due to the lack of reliable validated biomarkers or surrogates for evaluating evidence of MRC dysfunction [14] , spectrophotometric assessment of MRC enzyme activities in a skeletal muscle biopsy or tissue from the disease-presenting organ if accessible is still considered the 'Gold Standard' biochemical method for diagnosing patients with MRC disorders. The status quo is set to exist until more effort and funding can be centered on identifying appropriate biomarkers that fulfill all criteria required to have diagnostic utility for detecting MRC disorders.
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